Wuhan Pharmaceutical Factory

Grandpharma (China), formerly known as Wuhan Pharmaceutical Factory, is a leading diversified pharmaceutical company based in Wuhan, China. Established in 1939, the company has transitioned from a state-owned manufacturer to a core subsidiary of the Hong Kong-listed Grand Pharmaceutical Group. It specializes in several key therapeutic areas, including cerebro-cardiovascular emergency medicine, ophthalmology, otorhinolaryngology, and innovative oncology treatments. Grandpharma is particularly recognized for its strategic expansion into the radiopharmaceutical sector through global partnerships and acquisitions. The company maintains large-scale manufacturing capabilities and a comprehensive R&D pipeline focused on both small molecules and advanced biologics. It is one of the largest producers of essential medicines and active pharmaceutical ingredients in China, including adrenaline and other critical care drugs.